Andriy Gnylorybov

Andriy Gnylorybov

Auto-generated profile, based on publicly available information

Andriy Gnylorybov

M. Amosov National Institute of Cardiovascular Surgery, National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2016 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
WPWon Park
Won Park
DYDae-Hyun Yoo
Dae-Hyun Yoo
JJJanusz Jaworski
Janusz Jaworski
JBJan Brzezicki
Jan Brzezicki
AGAndriy Gnylorybov
Andriy Gnylorybov
JBJürgen Braun
Jürgen Braun
CT-P13 (Remsima®, Inflectra®) is a biosimilar of the infliximab reference product (RP; Remicade®) and is approved in Europe and elsewhere, mostly for the same indications as RP. The aim of this study was to compare the 54-week efficacy, immunogenicity, pharmacokinetics (PK) and safety of CT-P13 with RP in patients with ankylosing spondylitis (AS), with a focus on patient-reported outcomes (PROs). This was a multinational, double-blind, parallel-group study in patients with active AS. Participants were randomized (1:1) to receive CT-P13 (5 mg/kg) or RP (5 mg/kg) at weeks 0, 2, 6 and then every 8 weeks up to week 54. To assess responses, standardized assessment tools were used with an intention-to-treat analysis of observed data. Anti-drug antibodies (ADAs), PK parameters, and safety outcomes were also assessed. Of 250 randomized patients (n = 125 per group), 210 (84.0 %) completed 54 weeks of treatment, with similar completion rates between groups. At week 54, Assessment of Spondylo Arthritis international Society (ASAS)20 response, ASAS40 response and ASAS partial remission were comparable between treatment groups. Changes from baseline in PROs such as mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI; CT-P13 −3.1 versus RP −2.8), Bath Ankylosing Spondylitis Functional Index (BASFI; −2.9 versus –2.7), and Short Form Health Survey (SF-36) scores (9.26 versus 10.13 for physical component summary; 7.30 versus 6.54 for mental component summary) were similar between treatment groups. At 54 weeks, 19.5 % and 23.0 % of patients receiving CT-P13 and RP, respectively, had ADAs. All observed PK parameters of CT-P13 and RP, including maximum and minimum serum concentrations, were similar through 54 weeks. The influence of ADAs on PK was similar in the two treatment groups. Most adverse events were mild or moderate in severity. There was no notable difference between treatment groups in the incidence of adverse events, serious adverse events, infections and infusion-related reactions. CT-P13 and RP have highly comparable efficacy (including PROs) and PK up to week 54. Over a 1-year period, CT-P13 was well tolerated and displayed a safety profile comparable to RP; no differences in immunogenicity were observed. ClinicalTrials.gov identifier: NCT01220518 . Registered 4 October 2010.

19 November 2013 in Lupus
Verified
Journal Article
Open access
ENE Nasonov
E Nasonov
SSS Soloviev
S Soloviev
JDJe Davidson
Je Davidson
ALA Lila
A Lila
RIR Ivanova
R Ivanova
MPMhs Pereira
Mhs Pereira
We assessed the prevalence and incidence of Systemic Lupus Erythematosus (SLE) in 2010 in adults from four cities in Russia, Kazakhstan and Ukraine. Individuals with SLE were identified retrospectively from the medical records of specialized centers. Prevalent SLE patients were nondeceased city residents, diagnosed prior to December 31, 2010; incident patients were residents newly diagnosed between January 1 and December 31, 2010. Population size was obtained from official census data. The observed prevalence rates (per 100,000, 95% CI) were 9.0 (7.1–11.2) in Kursk and Yaroslavl, Russian Federation; 20.6 (15.4–27.0) in Semey, Kazakhstan; and 14.9 (10.9–19.9) in Vinnitsa, Ukraine. The cumulative incidence rates (per 100,000, 95% CI) were 1.4 (0.7–2.4); 1.6 (0.4–4.1) and 0.3 (0.0–1.8), correspondingly. All rates were higher among females compared to males, and incidence peaked in the population aged 25–44. These rates appear slightly lower than those reported from Western Europe and the USA. This could be because of study design (case-ascertainment), local health care practices or true differences in disease risk. Case age and sex distribution was similar to the known epidemiology of SLE. The rates were highest in Kazakhstan, likely because of a predominantly ethnic Asian population.

1 June 2013 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
WPW. Park
W. Park
JJJ. Jaworski
J. Jaworski
JBJ. Brzezicki
J. Brzezicki
AGA. Gnylorybov
A. Gnylorybov
VKV. Kadinov
V. Kadinov
JBJ. Braun
J. Braun
Background CT-P13 is a biosimilar product of infliximab (INX). Data up to week 30 has been reported at EULAR 2012.1 Objectives To assess the PK, efficacy and safety of CT-P13 in patients with active AS up to week 54 and to compare this with INX, also in relation to the formation of anti-drug antibodies (ADAs). Methods Patients with active AS (1984 modified NY criteria) were randomised (1:1) to receive either CT-P13 (5mg/kg) or INX (5mg/kg) at weeks 0, 2, 6 and then every 8 weeks up to week 54. Results Of 250 patients randomised at baseline, 213 patients were treated up to week 54. Cmax of CT-P13 and INX were shown to be equivalent, since 90% CIs for the ratio of geometric means were within 80–125% at all doses (CT-P13, 128.1µg/mL–172.2µg/mL; INX, 123.0µg/mL–176.7µg/mL). At week 54, the proportion of patients testing positive for ADAs was comparable between CT-P13 and INX (22.9% [25/109] vs 26.7% [28/105]). ADAs had similar effects on PKs in both groups. Patients with negative ADA results had higher Cmax values (CT-P13, 134.5µg/mL–177.2µg/mL; INX, 131.9µg/mL–177.4µg/mL) compared with patients with positive results (CT-P13, 101.8µg/mL–160.4µg/mL; INX, 104.0µg/mL–175.2µg/mL). At week 54, ASAS40 and ASAS partial remission were comparable between groups (CT-P13, 54.7% and 19.8%; INX, 49.1% and 17.6%, respectively). More patients with negative ADA results achieved ASAS40 responses (CT-P13, 61.0%; IFX, 54.7%) compared with patients with positive results (CT-P13, 37.9%; IFX, 36.4%). The safety profiles of CT-P13 and INX were also comparable (table). Active tuberculosis (TB) was reported in 3 patients (CT-P13, 2; INX, 1) and there were no malignancies. Conclusions CT-P13 has similar PK values and a clinical efficacy comparable to INX up to week 54. CT-P13 was well tolerated with a safety profile comparable to that of INX up to 54 weeks. ADAs seem to diminish the clinical response to both agents in some patients. References Park W et al. A randomised, double-blind, phase 1 study demonstrates equivalence in pharmacokinetics, safety and efficacy of CT-P13 and infliximab in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71(Suppl 3):111. Disclosure of Interest W. Park Consultant for: CELLTRION Inc., J. Jaworski Grant/research support from: CELLTRION Inc., J. Brzezicki Grant/research support from: CELLTRION Inc., A. Gnylorybov Grant/research support from: CELLTRION Inc., V. Kadinov Grant/research support from: CELLTRION Inc., I. Goecke Sariego Grant/research support from: CELLTRION Inc., C. Abud-Mendoza Grant/research support from: CELLTRION Inc., W. J. Otero Escalante Grant/research support from: CELLTRION Inc., S. W. Kang Grant/research support from: CELLTRION Inc., D. Andersone Grant/research support from: CELLTRION Inc., F. Blanco Grant/research support from: CELLTRION Inc., D. H. Yoo Consultant for: CELLTRION Inc., C. Ahn Consultant for: CELLTRION Inc., Speakers bureau: CELLTRION Inc., H. U. Kim Employee of: CELLTRION Inc., J. Braun Consultant for: CELLTRION Inc., Speakers bureau: CELLTRION Inc.

19 February 2015 in Lupus Science & Medicine
Verified
Journal Article
Open access
PDF file
ENE Nasonov
E Nasonov
SSS Soloviev
S Soloviev
JDJ E Davidson
J E Davidson
ALA Lila
A Lila
GTG Togizbayev
G Togizbayev
MPM H S Pereira
M H S Pereira
Objectives To describe disease characteristics and treatment regimens for adult patients with systemic lupus erythematosus (SLE) with autoantibody positive disease in three countries (the Russian Federation, Ukraine and Republic of Kazakhstan). Methods The ESSENCE study was a 1-year, retrospective, multicentre, observational study. Data included patients’ characteristics, disease activity and severity, and healthcare resource use in 2010. Results Twelve centres enrolled 436 eligible patients: 232 in Russia, 110 in Kazakhstan and 94 in Ukraine. Mean age ranged from 36 to 42 years and median SLE duration from 3 to 6.8 years. According to study definitions, 69.2% of patients in Russia, 72.7% in Kazakhstan and 55.4% in Ukraine had severe disease at diagnosis. SLE activity (Nasonova classification, 1972) decreased from diagnosis to the last visit in 2010 in all countries. At the last visit, mean (SD) Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index score was 13.8 (10.5) in Russia, 19.4 (16.9) in Kazakhstan and 7.2 (6.8) in Ukraine, and Systemic Lupus International Collaborative Clinics/American College of Rheumatology damage index was 2.0 (2.2), 3.3 (3.2) and 2.2 (2.0), respectively. Treatment regimens included predominantly glucocorticoids (96.7–99.1%), immunosuppressants or cytotoxic drugs, for example, azathioprine and cyclophosphamide (20.7–53.2%), and antimalarial drugs (18.3–40.8%). Conclusions The study provides reliable insight into the SLE clinical profiles in the referenced countries. Patients were 4–10 years younger in the study and had 3–7 years shorter SLE duration than in Western European countries and both SLE activity and severity were higher with higher rate of hospitalisations, but decreased during treatment. Local and international scales demonstrated correlation in SLE activity and organ damage evaluation. There were differences in clinical characteristics and healthcare features across the countries.

1 January 2020 in Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
AGAndriy M Gnylorybov
Andriy M Gnylorybov
STSemen K Ter-Vartanian
Semen K Ter-Vartanian
IGIrina Y Golovach
Irina Y Golovach
OVOleg E Vyrva
Oleg E Vyrva
OBOleksandr A Burianov
Oleksandr A Burianov
KGKnarik V Ginosyan
Knarik V Ginosyan
Objective: The present work was led by a multidisciplinary panel of experts and proposes an extensive review on the use of prescription crystalline glucosamine sulfate (pCGS) in the multimodal treatment of osteoarthritis (OA) applicable in Ukraine and other Commonwealth of Independent States (CIS) countries. Methods: A panel of rheumatologists, orthopedic surgeons, and field experts from Ukraine and CIS regions discussed the management of OA. Literature was systematically searched using Medline, EMBASE, CIHNAL, and Cochrane Library databases. The 2-day meeting critically reviewed the available literature, treatment algorithms, pharmacoeconomic aspects, and real-world instances to form a multimodal approach based both on real-life clinical practice and systematic literature research for the management of OA in Ukraine and CIS countries. Expert Opinion: pCGS plays a pivotal role in the stepwise approach to OA treatment. If it is necessary (step 1), the combined use of pCGS with paracetamol and topical nonsteroidal anti-inflammatory drugs (NSAIDs) has been recommended. If symptoms persist, oral NSAIDs and intra-articular (IA) hyaluronic acid or corticosteroids are added to the therapy (step 2) of pCGS in the patients. In case of insufficient relief and severe OA (step 3), pCGS along with oral NSAIDs, IA corticosteroids, and duloxetine have been recommended. Patient stratification with regular monitoring and careful alterations in treatment were advocated. Conclusions: This expert opinion article recommends a modified approach to the existing guidelines incorporating pCGS in treatment modality of OA in Ukraine and CIS countries. Extensive use of pCGS targets early symptomatic relief in OA while limiting the adverse effects due to long-term use of analgesics and NSAIDs.

10 January 2014 in British Journal of Medicine and Medical Research
Verified
Journal Article
Open access
PDF file
KGK. Gatina
K. Gatina
EBE. Barinov
E. Barinov
OSO. Sulaieva
O. Sulaieva
AGA. Gnylorybov
A. Gnylorybov
YHY. Hushchyna
Y. Hushchyna
AMA. Menzarar
A. Menzarar
Aim: To investigate the role of platelet adrenoreactivity in development of hyperreactive platelet phenotype in patients with myocardial infarction receiving antiplatelet therapy. Study Design: Cohort prospective study. Place and Duration of Study: Histology Department of Donetsk National medical university; Institute of Emergent and Rehabilitation Medicine, Donetsk, Ukraine, between June 2011 and September 2013. Methodology: The study was carried out on 36 patients with acute ST-elevation MI receiving double antiplatelet treatment. After assessment of epinephrine (5 µM) induced aggregation two groups of patients were identified: with high (1st group, with aggregation more than 40%) and low (2nd group, aggregation less than 40%) adrenoreactivity. Within both groups platelets’ reaction to the main agents (ADP (5 mkM), collagen (5mkg/ml), ristocetin (0.5mg/ml); thrombin (1U/ml)), was measured. Since a mixture of agonists in low concentration is present at the site of coronary arteries occlusion, subthreshold concentrations of agonists were used in addition to EC50 in order to analyze their potentiating effect on aggregation. 10 healthy volunteers were taken as a control group. The results were analyzed using MedCalc software. Results: 75% (27) of patients with MI on double antiplatelet therapy developed hyperreactivity to epinephrine. Comparison of platelet reactivity among the patients with high and low adrenoreactivity showed that hypere adrenoreactivity phenomenon was associated with higher platelet response to ADP, as well as to adhesive agents (ristocetin and collagen). Whereas subthreshold concentration did not exhibit much potentiating effect among the patients with low initial adrenoreactivity, hyper adrenoreactive patients exhibited rather powerful potentiation of effects of ADP and epinephrine. Conclusion: Adrenoreactivity plays an important role in the responsiveness to different agonists and could be a mechanism of tolerance/resistance to antiplatelet therapy among the patients with MI.